company background image
1498 logo

PuraPharm SEHK:1498 Stock Report

Last Price

HK$0.60

Market Cap

HK$237.0m

7D

1.7%

1Y

-36.2%

Updated

21 Dec, 2024

Data

Company Financials

PuraPharm Corporation Limited

SEHK:1498 Stock Report

Market Cap: HK$237.0m

1498 Stock Overview

An investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. More details

1498 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

PuraPharm Corporation Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for PuraPharm
Historical stock prices
Current Share PriceHK$0.60
52 Week HighHK$0.95
52 Week LowHK$0.51
Beta0.18
1 Month Change-6.25%
3 Month Change-10.45%
1 Year Change-36.17%
3 Year Change-22.08%
5 Year Change-53.85%
Change since IPO-84.33%

Recent News & Updates

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

Feb 06
Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

Is PuraPharm (HKG:1498) A Risky Investment?

Sep 28
Is PuraPharm (HKG:1498) A Risky Investment?

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

Nov 02
PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

Is PuraPharm (HKG:1498) A Risky Investment?

Aug 23
Is PuraPharm (HKG:1498) A Risky Investment?

PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues

Apr 01
PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues

How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?

Dec 27
How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?

Shareholder Returns

1498HK PharmaceuticalsHK Market
7D1.7%-1.9%-0.5%
1Y-36.2%-3.9%19.9%

Return vs Industry: 1498 underperformed the Hong Kong Pharmaceuticals industry which returned -3.9% over the past year.

Return vs Market: 1498 underperformed the Hong Kong Market which returned 19.9% over the past year.

Price Volatility

Is 1498's price volatile compared to industry and market?
1498 volatility
1498 Average Weekly Movement6.4%
Pharmaceuticals Industry Average Movement6.4%
Market Average Movement8.8%
10% most volatile stocks in HK Market18.6%
10% least volatile stocks in HK Market4.1%

Stable Share Price: 1498 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 1498's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998525Abraham Chanwww.purapharm.com

PuraPharm Corporation Limited, an investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Oncozac, Haveron, and Immuzac brand names.

PuraPharm Corporation Limited Fundamentals Summary

How do PuraPharm's earnings and revenue compare to its market cap?
1498 fundamental statistics
Market capHK$237.03m
Earnings (TTM)-HK$87.09m
Revenue (TTM)HK$419.41m

0.6x

P/S Ratio

-2.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1498 income statement (TTM)
RevenueHK$419.41m
Cost of RevenueHK$194.76m
Gross ProfitHK$224.65m
Other ExpensesHK$311.74m
Earnings-HK$87.09m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.22
Gross Margin53.56%
Net Profit Margin-20.77%
Debt/Equity Ratio289.5%

How did 1498 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 04:32
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PuraPharm Corporation Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBOCOM International Securities Limited
Wai Ming KongDBS Vickers Research
Ajeya PatilEvaluate Research Limited